The patient was treated with cholinesterase inhibitors, licensed for the treatment of mild-to-moderate AD in this jurisdiction, but these produced no subjective or objective benefit despite switching between the different cholinesterase inhibitors [10]. Here, BCHE is linked to Alzheimer disease.